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El7451 TheIsoeleotrlcWindowAfterDefibrillationShocks:Is It TrulyElectricallyQuiescent?
N.Chaftipakom,B.H.KenKnight,W.M.Smith,R.E.Ideker.Un/vers/fyof
Alabamaat Birmingham,AL, USA
Praviousstudieshavereportedanisoeleafricwindowlasting40-100msafter
defibrillationshocksafterwhichan activationfrontarisesin oneregion(the
siteof earliestactivation,EA)andpropagatesacrossthe entireepicardium.
Wesoughtto defermlnewhetherthe Isoelactrlcwindowis reallyelectrically
silentor whetheractivationoocursduringthis intervalbut onlypropagates
locally(Locally-PropagatedAclivity,LPA)In a smallregionbeforeit blocks
and is extinguished.Sequencesof epicardialactivationsweremappedbe-
fore and.afterattempteddefibrillation(RV-SVCCOIIS)withblphasicshocks
havingstrengthneardefibrillationthreshold(DFT)in5 pigs.Unipolarepicar-
dial eleorrograms~(t)] wereaoquiredfroma 504electrodesock(s 4 mm
Irttereleotrodespacing)pulledovertheventricles.in eachanimal,10shocks
at DFTweredeliveredafter 10 s of VF induofion.Localactivationswere
definedby dV/dts –0.5 V/sand weredetectablestarting20 msafterthe
shock.Resrdts:LPAswereobservedfollowingall su&essful(S)andfailed
(F) shocks.LPAsoccurredin 3 + 3 regionsand eachregionoentained7
+ 6 recordingelectrodes.Whilethe timeafterthe shockwasnotdifferent
for the appearanceof EAs(64 + 10’ms for S and 62 + 9 msfor F) the
timeof appearancewasdifferent(P < 0.001)for S LPAs(41+ 16ms)than
F LPAs(35+ 8 ins). Conclusion:The isoelectricwindowis not electrically
siient.LPAsexistwithsuccessfulandfailedshocksnearthe DFTthatcan
only propagate100allybeforebiooklngand extinguishing.EarlyLPAsmay
causeagreaterdispersionof refrsctorinesethaniateLPAswhichmeycause
activationarisingfromEAsto blockandreenter,leadingto theresumptionof
fibrillationfollowingfailedshocks.
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m ‘mprOvd*fe~OfTrsnevenOusAtrislDefibriilstiOnDuringWideQRSTabhycsrdlsbyIntroductionofs
DaisyInterval
A. Natsle,K.H.Newby,J. Brsndon,M.Kearney,P.H.Henderson,
A.Wolverton,S.Beheiry,R.Fanelli,E.Pisano’.DukeUniversityMedics/
CenterrVAMedicalCentecDurham,NC,USA,CaseSollievoDella
Soffererrza,SanGiovanniRotondo,/ta/y
AtrialdefibrillationduringwideQRScomplextachycardiahasa higherlikeli-
hoodto causeventricularfibrillation.In 10patientsundergoingatrialdefibril-
lation,weassessedwhetherthesafetyofatrialdefibrillationduringwideQRS
hchycerdiacouldbe improvedby deliveringthe shockaftara fixeddelay
fromtheseneedrightventricularelectrogram.Atrfalfibrillationwasperformed
usingtwonona-pdarcathetersplacedintherightatriumandcoronarysinus,
respectively.Afterappropriatesensingof the localrightventricularelectro-
grsmwseverified,atrialdefibrillationthresholdwasobtained.Ineachpatient,
atriaidefibrillationweesubsequentlyattemptedduringventricularpacingat
2~ mssccyclelengthby triggeringshocksat theatrialdefibrillationenergy
ievelonthebeginningof the100alventricularelectrogramandaftera 50and
70msecdelaysfromthesamerecording.Shocksynchronizedonbsginning
ofthelocalrfghtventticularelectrogramproduceddegenerationtoventricular
fibrillationin 7 out of 10 patients.Whenatrfaldefibrillationwasperformed
givingtheshocks50msecafterthebeginningof therightventricularelaotro-
grsmprosrrhyfhmiaweeseenin 1patientoutof 10.Noneofthepatientshad
shock-inducedproarrhythmiausinga delayof 70 msec.Inconclusion,atrfal
defibrillationaftera fixeddelayfromthe beginningof the sensedrightven-
tricularelactrogrsmmayreducethe riskof proarrhythmiafollowingshocks
deliveredduringwideQRScomplextachycardia.
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El7453 EfficacyofSotslolandMetoprotolin Patientswith
sn ImplantedCardioverterDefibrillator
v. KCrhlkamp,C. Mewis,V.D6,mberger,R.Suchalla,J.Memi,L.SeiPel.
MedicalDepartmentIll, UniversifyofTObingen,Germany
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efficacyis due to its betablockingactivityor its olassthree antiarrhythmic
effect.Weanalyzedin a prospectiverandomizedstudytha clinicaleflioaoy
of SOTin comparisonto the betablwkermetoprckd(MET)in 112petients
(P)withan implantedcerdiovefierdefibrillator.In all P SOTdid not prevent
inductionofVTVFduringalectrophysiologictesting.Thegroupsdidnotdiffer
in respectto age,underlyingcardiacdisease(COp = 0.53),leftventricular
function(EF,p = 0.72)orcllnicalarrhythmia(VTIVF,p = 0.41).
Age CD EF VTIVF
SOtalOl(n =55) 61 + 734 CAD (67%)10 DCM (18%) 37+ 1429 (49%)/26 (51%)
M@oprolol(n=57) 63+8 43 CAD (77%) 8 DCM (11%) 38+ 1433 (58%)/24 (42%)
Meanfoiiow-upin PtreatadwithSOTwas691+ 537days,in Preceiving
METthefollow-upwas742+ S05days(p= 0.42).51%of the Ptreatedwith
SOThada VTNFepiscde(follow-upof 208+ 328days)oomparedto 47%
of PtreatedwithMET(follow-up238+ 232days,p = 0.33).1 P in the SOT
grouphada torsadesdepointes.
Cono/usiorr:Thepurebeta-blockerMetoprololisaseffectiveasSotalolin
preventingrecurrencesof VTNF in patientswithan implantedcardioverter
defibrillator.
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n Defibr,,,.iiO.VVi*hDifferentEnergyl.evelsand ““”
DuringSleep:Impacton PainPerception
A. Natale,K.H.Newby,J. Brsndon,M. Keamey,S. Beheiry,
P,H,Henderson,A.Wolverton,R.Fanelii,E.Pisano’,DukeUrr/vers/ty
MedicalCtvrterALAMedicalGemecDurham,NC,USA,CasaSollievoDe//e
~Off.9A3nZiS,SanffiovarmiRotondo,Italy
Diwmfort followingdefibrillationshocksremainsa significantoonoemand
mayreducepatientacceptanceof Impiarrtabladevicesfor attial fibrillation.
Weassessedwhethershocksof differentenergylevelsor deliveredat night
duringsleepcouidreducethe perceptionof pain. In 29 patientswith im-
planfebiedefibrillator,shocksof 1 end5 Joules(group1-10 patients),and
of 5 and 10Joulas(group2-19 patients)wererandomlydeliveredwiththe
patientsawake.In group2, the 10Joulesshockwasdeliveredagaindur-
ingthe nightwhilepatientswereaaleep.Patientswereaskedto gradethe
intensityof discomfortusingtwodifferentscales(fromoneto ten, andfmm
absento exfremeiysevere).Patientswerealsoaskedif theytoleratedbetter
theasieapvs.theawakeshmk. Nodifferencein discomfotiwasreportedin
group 1 between 1 and 5 Joules (aCore 1 Joule &3 + 1.9 ve 5 Joules &O +
2.1,p = NS)andingroup2 between5 and10Jouiesshocks(score5 Joules.
6.1 + 2.2 vs 10Joules5.6 + 2.0, p = NS).Usuallythe secondshockwas
perceivedasstrongerregardlessof theenergyused(p < 0.0005).In 14pe-
tientsshockduringsleepwasbettertolerated(p c 0.0001),3 patientsdidnot
reportanydifference,andtheremainingtwopatientsfeltmoreuncomfortable
dueto theirsubsequentinabilityto fallasleepagain.In conclusion:(1)atrial
defibrillationduringsleepmayreducethediscomfortassociatedwithenergy
delivery;and (2)shockswithenergylevelsof 1 to 10Joulesdo notappear
to beperceiveddifferently.
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D7455 DualCurrentPathwaysfor InternalAtrislDefibrillationinSheep:MarkedReductionin
DefibrillationThreshold
R.A.S.Cooper,W.M.Smith,R.E.Ideker.TheUniversityofA/abamaat
Birmingham,Birmingham,Alabama,USA
Thepurposeof thisstudywazlo comparethe atrialdefibrillationefficacies
of multiplesingleanddualcurrentpathways.In6 adultsheep,transvenous
defibrillationelectrodeswerepositionedintherightatrialappendage(RAap),
51
*.Psoos
.sotalol(SOT)is the mostimportantantiarrhyfhmicdrugfor thetreatmentof
sustainedventriculartachyarrhyfhmias.Howeverit is unknownwhetherits
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distal Coronarysinus (DCS), proximal coronary sinus (CSOS),left pulmonary
artery (LPA), and right ventricular apex (RV). 7 single and 7 dual currant
pathways were compared. Single capacitor biphasicwaveforms (3ma/1 ms in
duration) were deliverad through each current pathway after atrial fibrillation
induction with rapid atrial pacing. Probability of success curves were than
determined by giving 10 shocks for each waveform starting at threshold.
The mean and standard deviation of the total delivered energy for the 50%
success pointa (E50) for each electrode configuration are shown (Fig.). Dual
current pathway “H” (0.35 * 0.16 joules) had a lower E50 than all other
single (A-G) and dual current (I-N) pathway configurations tested. Compared
to the single current pathway (“A”) being employed with the first implantable
atrial defibrillator, atrial defibrillation thresholds can be markedly reduced by
using dual current pathways. With more efficient electrode configurations, the
discomfort of internal atrfal defibrillation shocks might be further minimized.
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El7456 Metoprololis MoreEffectivethsnd,lSotslolforPreventionof Recurrenceof Ventricular
TechyarrhythmissafterImplantationofa
Cardioverter/Defibrillator
K. Seidl, B. Hauer, N. Schwick, S. Polak, 6. Hfigl, J. Senges. I-/erzzerdnrn
Ludwigshafen, Cardiology, Germany
About 20-50% of patients (pts) with an implantable eerdiover’teddefibrillator
(lCD) are additional treated with antiarrhythmic drugs to prevent frequent
ICD discharges. The purpose of this prospective randomized study was
to evaluate the efficacy of d,l sotalol (Sot) and metoprolol (Met) regarding
the recurrence of arrhythmia events and death after implantation of a car-
diovetier/defibrillator. After ICD implantation 70 pts were randomly assigned
to either Met (104 * 37 mgddayin 35 pts) or Sot (242 + 109 mglday in 35
pts). Both groups were comparable for sex, age, ejeclion fraction, extent of
etruotural heart dieease and presenting arrhythmia.
Resu/ts: Met treatment led to a marked reduction in the recurrence of
ventricular tachycerdia (VT) or fibrillation (VF) ae mmparad to Sot during a
follow-up of 26 + 16 months. Whereas 80% of the pta in the Met group were
free of VT recurrence only 51% of the pts treatad with Sot were free of VT
recurrence (p = 0.02). Actuarial rate for freedom of fact VT or VF were 60%
in the Met group compared with 46% in the Sot group (p = 0.0016). During
follow-up there were 3 death in the Met treated pts compared to 6 death in
the Sot arm. Actuarial ratee for overall survival were not different (917. vs
83%, p = 0.29).
Corrc/usiorrs:ln thierandomized study the recurrence rate of life threaten-
ing ventricular tachyarrhythmias after ICD implantation is lower in pts treated
with Met than in pte treated with Sot.
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NormslReetTetrofosminSPECTImeginginPatients
withChestPainsndNormalorNondiegnosticECG
inthe EmergencyDepatlmentisAssociatedwith
LowerNeedforSubsequentCerdiacCatheterization
andRevaacularizstion
F.J.Th. Wackere, GY. Heller, S. Stowers, R.C. Hendel, S. Herman,
J. Baron, E. Daher, for the Acute Chest Pain TetrofosminTrial. Ya/eUni~,
New Haven, CT, USA
We have demonstrated in a multicenter trial that rest Tc-99m Tetrofosmin
(Tetro) SPECT myocardial perfusion imaging in the emergency department
(ED) in patients (pte) with chest pain and normal or nondiagnostic ECG has
a high negative predictive value (96Yo)for the detection of acute infarction
(Ml). In order to determine the prognostic value of ED Tetro SPECT and the
clinical relevance of “missing” Ml’s, 357 pts with chest pain and normal or
nondiagnostic ECG, who had rest Tetro SPECT in ED had follow-up (FU)
in-hospital (IH) and for 30 days (30 d). ED SPECT imaging was normal in
295 pts (63%) and abnormal in 62 pte (17%). All pts were admitted to rule out
Ml. Managing physicians were blinded to SPECT imaging resulta. Primary
endpoints were ischemic death.and recurrent Ml, a eecondary endpoint was
revascularization (Revasc). FU was 100% Complete IH, and 91% complete
for being alive at LXId.
Events IH (# pts) 30d (# pts) Total (# pts)
Death o 0 0
Ml 20 0 20
Cath Ss s 96
Revasc 24 2 36
At 30 d follow-up, pts with abnormal ED Tetro SPECT had significantly
more acute Ml (21Y0vs. 2%, p < 0.001), more cardiac catheterization (43%
vs. 23%, p =0.002), and more Revasc (23% vs. 7%, p < 0.001) than pts with
normal rest ED Tetro SPECT. Thus, abnormal rest ED Tetro SPECT in pts
with chest pain and normal or nondiagnoetic ECG identified a subgroup of
patients with higher cardiac eathaterization rate and higher clinical need for
Revasc during subsequent 30 d follow-up. Conversely, pts with normal ED
SPECT are at relatively low risk for Revasc.
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~] EsrlYScinti9raPhic~etectionofAWte MYOcardiai
Infarctsin Humans.A Technetium-99m-Glucsric
Acid(ggmTc-GA)Study
C. Brunelli, P,Spellarossa, P,Rossettin, G. Villa, C. Motta, G.P. Bezante,
G. Caleagno, L. Coraiglia, G. Mariani, S. Caponnetto. Daparfrner?tof
/nterna/ Medicine, Urriveraifyof Genoa, /fa/y
Background: Experimental studies demonstrated that ‘gmTc-GAmaybauaed
to deteet acute myocardial infarction (AMI) in canine models with temporary
artery occlusion. In these studies, ggmTc.GAshowed increased affinity for
necrotic myocardial tissue (infarct-avid imaging) without marked liver and
osseous structure uptake.
Aim of the study; To examine the utility of ‘gmTc-GA as a myoeardial
imaging agent in patients (pte) with severe myocardial isohemia Methods:
Seventeen pts(mean age59+ 11years) with prolonged cheat pain (>60 rein)
and ST segment elevation (>0.2 mV in two adjacent leads) were considered
for the etudy.9gmTc-GAwae administered as a single bolus iv injection (900-
1000 Mbq) within 2-41 hours (mean 10, median 7) from onset of symptoms.
Planar images wera acquired 3 hours after administration in three standard
projections (Ant, LAO, LL), about 2 million counts in the field of view. Resu/ts:
99MTC-GAuptakewasclearly identified in 10 pts (Scan+). All Scan+ pts were
injected within 9 hours (mean 5.1) from symptoms. A diagnosis of AMI was
enzymatieally confirmed (CK peak value twice or more the upper limit of the
normal range [190 U/l]) in all but one Scan+ pts. This pt reached a CK peak
value of 350 WI which can be considered borderfine. Seven pta showact a
negative uptake (Scan–). Five of them had a confirmed AMI but were late
injected (within 13-41 hours from eymptoms). In the remaining two Scan-
pts who were injected 6 and 9 hours from symptoms, the diagnosis of AMI
was not confirmed by serum enzymee. Five pts who were acutely Scan+
underwent one month later a second scintigraphic study that did not show
area of ‘gmTc-GA uptake. Conclusions: Theee date confirm the potential
of ‘mTc-GA ae a direct scintigraphic indicator of acute myocardial neercwis.
99fnTc.GA~uld beimpo~antwhenruling out AMI in ptewith unetable angina.
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1746-31Technetium-99m*s@mibi,nfarc~si~epred,cts
Mortality
T.D. Miller, D.O. Hedge, J.M. Sutton, C.L. Grines, J.H. O’Keefe,
M.A. DeWood, R.D. Okada, W.O. Fletcher, R.J. Gibbons. Mayo Clinic,
Rochestec MN, USA
A previous Mayo Clinic study demonstrated that quantitative tomographic
Technetium (Tc)-99msestamibi infarct size measured at hospital discharge
predicts subsequent mortality. The purpose of the present study was to
provide independent confirmation of thie finding in a separate, multicenter
population. Twohundrad eight patients (1”53M, 55 F,age 62 + 11years) from
23 different medical centers (no Mayo patients), all of whom were treated
acutely with thrombolysis or PTCA, were”followed for a minimum dutation of
6 months after myoeardial infarction. Tomographic Tc-99m sestamibi aeana
performed at hospital discharge in each center were procesaed and quanti-
tatad using previously published methods at a core laboratory. Median infarct
size was 14% Of the left VentriCle(25th percentile 3%, 75th percentile 27Yo).
Seventeen patients died during follow-up. Infarct size was significantly as-
sociated with subsequent mortality (X2 = 7.39, p = 0.007). Mortality rates
were:
Group 3 Month 6 Month 12 month
Entirestudygroup 4“/0 5% 6%
Infarctsize <14% 1% 2% 2%
Infarctsize 214°A s% s% 9%
